Patent · US Active

Compounds for inhibiting cell proliferation in EGFR-driven cancers

US9834518B2 · kind B2 · utility

2Cited by
50References
2Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 4, 2012
Grant dateDec 5, 2017
Priority date—
Expiry dateNov 5, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D413/12
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula I:wherein the variables are as defined herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.